Revolution Medicines Director Lorence H. Kim Sells $3.59M in RVMD via 10b5-1 Plan

Insider Transaction Summary

• Reporting Owner: Lorence H. Kim
• Role: Director
• Company: Revolution Medicines, Inc. (RVMD)
• Filing Date: September 10, 2026
• Transaction Date: September 8, 2026

Transaction Details

Director Lorence H. Kim executed open-market sales totaling 17,090 shares of Common Stock held indirectly through the Lorence Kim Revocable Trust. The sales took place across multiple weighted-average price tiers ranging from $206.60 to $212.27, generating aggregate proceeds of approximately $3,585,837.

• 706 shares at an average price of $206.6049
• 999 shares at an average price of $207.3321
• 3,587 shares at an average price of $208.5534
• 2,853 shares at an average price of $209.5600
• 4,730 shares at an average price of $210.5028
• 3,844 shares at an average price of $211.3588
• 371 shares at an average price of $212.2693

Post-Transaction Holdings

• Indirect Holdings (Trust): 0 shares (100% liquidated)
• Direct Holdings: 1,191 restricted stock units (RSUs)

Analysis & Context

• Plan Trading: All transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on June 1, 2026.
• Significance: The disposition fully liquidates the Lorence Kim Revocable Trust's common share holdings, leaving only unvested direct equity awards. While the total liquidation of indirect shares represents a notable position change, the programmatic nature under a Rule 10b5-1 plan dampens discretionary market-timing signals.